PhosAgro CEO, Andrey Guryev explains why Russia's agricultural sector has fantastic potential.
A high demand and short supply of the green superfood have triggered an avocado-related crime wave in New Zealand.
A combination of buoyant demand and supply-side jitters is supporting prices of soybeans and corn after several years of glut-driven pessimism.
Bunge CEO Soren Schroder says agricultural commodities might be unpredictable but irrespective of price levels, demand continues to grow.
Janus Capital Group SVP Nick Cherney weighs in on Janus Capital launching four new health & wellness ETFs.
The drought wreaking havoc in Southeast Asia looks set to fall off the agenda at a key meeting of the region's political and financial leaders this week.
California's economy is on fire but the state's finances are another story and the governor is warning of a slowdown or recession down the road.
Stephen Macklow-Smith, head of Europe equities strategy at JPMorgan, and Steen Jakobsen, Saxo Bank chief economist, discuss Tate & Lyle and sugar.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
Kirsty Wilson, senior analyst at Mergermarket, looks at the potential bidders for U.S. agrichemicals giant Monsanto, including potential interest from China.
Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.
John Rountree, managing partner at Novasecta, talks about whether or not the Bayer-Monsanto merger would create more or less innovation and value.
Just when you thought the dearth of M&A in Europe was here to stay, Bayer sweeps in with a $62 billion bid for U.S. giant Monsanto.
Werner Baumann, Bayer CEO, weighs in on the tax ramification of the combined companies.
Werner Baumann, Bayer CEO, explain why he went public with the $62 billion bid for Monsanto.
CNBC's Nancy Hulgrave reports on Bayer's big move to create a global leader in agriculture.
How tough will it be for Bayer, to convince investors that the Monsanto bid is worth it? Dealreporter assistant editor, Alex Tarrant weighs in.
Werner Baumann, Bayer CEO, explains why he thinks the company's offer for Monsanto would likely pass regulatory scrutiny and doesn't see risk in the deal.
The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.
Shares of Deere fell about 5 percent despite posting better-than-expected earnings.